Bio-Techne Q4 Preview: NIH Funding Cut And Tariffs Impacts, Initiate At Sell

Summary

• Bio-Techne Corporation is a market leader in life science reagents, well-positioned for long-term growth in cell and gene therapeutics and organoid solutions.
• Despite strong fundamentals and recurring revenue, near-term risks from NIH funding cuts and U.S.-China tariffs are not fully priced in.
• My DCF analysis suggests TECH stock is overvalued, with a fair value of $48 per share versus current high multiples; I initiate with a Sell rating.
• While FDA regulatory changes and share repurchases offer upside, I expect management to provide a cautious FY26 outlook due to ongoing uncertainties.

Tom Werner/DigitalVision via Getty Images

Bio-Techne Corporation (NASDAQ:TECH) is the market leader in high-quality biological reagents used in the life science market, manufacturing high-quality proteins, antibodies and immunoassays. I think the company will benefit from the long-term growth in cell

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.